SEC Form 4 · accession 0001209191-17-066864
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Opko Health, Inc.
10% Owner
Period of report
Dec 19, 2017
Accepted (ET)
Dec 21, 2017 · 6:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 19, 2017 | A | 495,126 | — | A | 1,289,818 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 19, 2017, the Issuer, Sevion Sub Ltd. ("Acquisition Sub"), and Eloxx Pharmaceuticals Ltd. ("Eloxx"), completed the merger contemplated under that certain Merger Agreement dated May 31, 2017, and pursuant to which Acquisition Sub merged with and into Eloxx, with Eloxx becoming the surviving corporation and a wholly-owned subsidiary of the Issuer. At the effective time of the merger, shares held by existing Eloxx shareholders prior to the Merger was converted, on a pro rata basis, into the right to receive 20,316,656 shares of Issuer common stock, after giving effect to a 1-for-20 reverse stock split that was effected on December 19, 2017.